|
EP0888458A4
(en)
|
1996-02-20 |
2004-05-06 |
Sloan Kettering Institutefor C |
COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
|
|
US20110111424A1
(en)
*
|
2001-06-21 |
2011-05-12 |
Cell Signaling Technology, Inc. |
Analysis of ubiquitinated polypeptides
|
|
DE10244453A1
(de)
|
2002-09-24 |
2004-04-01 |
Phenomiques Gmbh |
Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
|
|
JP4653103B2
(ja)
|
2003-06-10 |
2011-03-16 |
ザ ジェイ．ディヴィッド グラッドストン インスティテューツ |
レンチウイルス感染症を治療するための方法
|
|
US8133666B2
(en)
|
2004-11-02 |
2012-03-13 |
The J. David Gladstone Institutes |
Method for identifying agents capable of inhibiting APOBEC3C activity in HIV-infected cells
|
|
US7429487B2
(en)
|
2005-07-05 |
2008-09-30 |
Epitomics, Inc. |
Fusion partner for production of monoclonal rabbit antibodies
|
|
AU2007257701A1
(en)
|
2006-06-15 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
2-anilino-4-aminoalkyleneaminopyrimidines
|
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
|
US7906117B2
(en)
*
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
WO2008144753A2
(en)
|
2007-05-21 |
2008-11-27 |
Alder Biopharmaceuticals, Inc. |
Antibodies to tnf alpha and use thereof
|
|
EP2036988A1
(en)
|
2007-09-12 |
2009-03-18 |
Siemens Healthcare Diagnostics GmbH |
A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
|
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
|
US9084762B2
(en)
*
|
2008-09-30 |
2015-07-21 |
The Regents Of The University Of California |
T-cell immunogens derived from anti-viral proteins and methods of using same
|
|
US20120252026A1
(en)
|
2011-04-01 |
2012-10-04 |
Harris Reuben S |
Cancer biomarker, diagnostic methods, and assay reagents
|
|
WO2013112601A1
(en)
|
2012-01-24 |
2013-08-01 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
|
WO2013118128A2
(en)
|
2012-02-12 |
2013-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Cellular apobec3 proteins and modulators thereof for regulating dna repair processes
|
|
WO2014028461A2
(en)
|
2012-08-13 |
2014-02-20 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
HU230680B1
(hu)
|
2012-10-19 |
2017-08-28 |
Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag |
Diagnosztikai eljárás
|
|
JP2016521711A
(ja)
*
|
2013-06-10 |
2016-07-25 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｃｍｖ中和抗原結合性タンパク質
|
|
WO2015032800A2
(en)
|
2013-09-03 |
2015-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for inducing senescence in cancer cells
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
GB201420859D0
(en)
|
2014-11-24 |
2015-01-07 |
Cancer Res Inst Royal |
Tumour analysis
|
|
WO2017004165A1
(en)
|
2015-06-29 |
2017-01-05 |
Regents Of The University Of Minnesota |
Apobec3b mutagenesis and immunotherapy
|
|
WO2017004151A1
(en)
|
2015-06-29 |
2017-01-05 |
Regents Of The University Of Minnesota |
Anti-apobec3 antibodies and methods of making and using
|
|
US20180185302A1
(en)
|
2015-06-30 |
2018-07-05 |
Regents Of The University Of Minnesota |
Methods for downregulating apobec3b
|
|
EP3433271A4
(en)
|
2016-03-23 |
2019-11-27 |
Regents of the University of Minnesota |
PROCEDURE FOR DETECTING APOBEC3 EXPRESSION AND PREDICTING CLINICAL RESULTS
|